Day: February 25, 2025

BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.    Corporate Update As previously disclosed in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company continues to have interactions with the FDA with the goal of addressing questions raised in the CRL.  Fourth Quarter and Year End Financial Results Research and development (R&D) expense: For the three months...

Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time...

Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2024, and recent business achievements. “Tarsus’ demonstrated category-creating...

Fourth Quarter 2024 Net Earnings of $18m, and Adjusted Earnings of $51m Completed upgrade of Odessa fleet, increasing total self-mining hashrate to ~13.5 EH/s Completed acquisition of Stingray data center site, featuring 100 MW of front-of-the-meter capacity, all necessary regulatory approvals, and 250 acres of land adjacent to transmission assets Completed acquisition of additional 337 acres of land adjacent to Barber Lake site and entered into 60-day exclusivity for negotiations to build an additional 500 MW HPC data center adjacent to the current site NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced its fourth quarter and full year 2024 financial results, with an update on its operations and business strategy. “We had an extremely productive fourth quarter...

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business HighlightsFourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023. Gross margin was 76.1% for the fourth quarter compared to 74.6% for the fourth quarter of 2023. Net income for the quarter was $0.4 million, or $0.01 per share, compared to net loss of $3.9 million, or $0.09 per share for the fourth quarter of 2023, on a fully diluted basis. Adjusted net income for the quarter was $3.5 million, or $0.07 per share, compared to...

Record Bookings in the Quarter of $219M Elevated Year-End Backlog to a Record $541MReaffirms 2025 Full Year Outlook ADDISON, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the fourth quarter and full year of 2024. Highlights for the Quarter(1)Orders of $218.9 million, up 71 percent Backlog of $540.9 million, up 46 percent Revenue of $158.6 million, up 3 percent Gross profit of $56.7 million, up 7 percent; Gross margin of 35.8 percent, up 120 basis points Net income of $4.9 million, up 26 percent; non-GAAP net income of $9.9 million, down 2 percent GAAP EPS (diluted) of $0.13, up 18 percent; non-GAAP EPS (diluted)...

Q4 revenue increased 16% year-over-year to a record $149 million driven by marketplace growth of 20% year-over-year.  Q4 gross profit increased 20% year-over-year to a record $59.0 million. Q4 marketplace gross profit increased 32% year-over-year driven by our AI technology and expanding supplier network. Q4 marketplace gross margin increased 320 basis points year-over-year to a record 34.5%. Q4 Adjusted EBITDA improved $3.9 million year-over-year to a profit of $1.0 million. Growth initiatives include: expanding buyer and supplier networks; driving deeper enterprise engagement; further expanding the marketplace menu; growing internationally and enhancing supplier services.NORTH BETHESDA, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting buyers with suppliers of manufacturing...

LITTLE ROCK, Ark., Feb. 25, 2025 (GLOBE NEWSWIRE) — Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced operating results for the 13 and 52 weeks ended February 1, 2025 (fiscal 2024). The Company follows the 4-5-4 retail reporting calendar, which included a 53rd week in the 2023 fiscal year. Comparisons are made based on the 13 and 52 weeks ended February 1, 2025 and February 3, 2024 where appropriate and noted. This release contains certain forward-looking statements.   Please refer to the Company’s cautionary statements included below under “Forward-Looking Information.” Dillard’s Chief Executive Officer William T. Dillard, II stated, “With sales down 1%, we worked on controlling expenses but lost some steam in gross margin.” Highlights of the Fourth Quarter (compared to the prior year fourth quarter):Total...